Skip to Content
Jordan D.  Berlin

Jordan D. Berlin, M.D.

Co-Leader, Gastrointestinal Cancer Research Program
Ingram Professor of Cancer Research
Professor of Medicine (Hematology/Oncology)
Director, Phase I Program
Medical Oncologist

  • Appointments
    Physicians: 1-877-936-8422
  • Clinical Trials Information
  • Other Telephone Numbers
    Henry-Joyce Cancer Clinic
    (615) 936-8422 or 1 (877) 936-8422

  • Faxes
    Henry-Joyce Cancer Clinic Fax
    (615) 343-8668
    Office Fax
    Clinic Fax
  • Addresses
    Henry-Joyce Cancer Clinic
    1301 Medical Center Drive, Suite 1710
    Nashville, Tennessee 37232-7415

    2220 Pierce Avenue
    777 Preston Building
    Nashville, TN 37232-6307

Jordan Berlin, M.D, is a medical oncologist who specializes in gastrointestinal cancers and investigational drug development (Phase I). In his roles as the Co-Leader of the Gastrointestinal (GI) Cancer Research Program and Director of Phase I Research at the Vanderbilt-Ingram Cancer Center, Dr. Berlin serves to coordinate clinical and translational efforts across the cancer center from the research programs to the phase I program as well as from within the GI program labs to GI program clinical trials. He is responsible for advancing preclinical data and investigational drugs to investigator-initiated trials and clinical evaluation. Dr. Berlin has extensive experience designing investigator-initiated and cooperative group trials as well as experience advising the pharmaceutical industry on trial design and development. Dr. Berlin is the PI of the VICC National Clinical Trials Network Lead Academic Participating Site Grant and the VICC PI of the VIKTriY multi-site UM1 grant led overall by Pat LoRusso at Yale Cancer Center. Additionally, as the immediate-past Medical Director of the Clinical Trials Shared Resource (CTSR), he mentors several junior investigators in phase I and GI malignancies and continues to mentor Vicki Keedy, M.D. in her role as current Medical Director of the CTSR.

  • University of Illinois, B.S. (Biochemistry), 1985
  • University of Illinois, M.D., 1989
  • Internship/Residency - Internal Medicine, University of Cincinnati Hospital, 1992
  • Fellowship, University of Wisconsin Hospital and Clinics; University of Cincinnati Hospital, 1995
  • Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.
    Available from:
  • Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J. Clin. Oncol [print-electronic]. 2014 Apr 4/20/2014; 32(12): 1277-80. PMID: 24638016, PII: JCO.2013.53.8009, DOI: 10.1200/JCO.2013.53.8009, ISSN: 1527-7755.
    Available from:
  • Goff LW, Thakkar N, Du L, Chan E, Tan BR, Cardin DB, McLeod HL, Berlin JD, Zehnbauer B, Fournier C, Picus J, Wang-Gillam A, Lee W, Lockhart AC. Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers. PLoS ONE. 2014; 9(9): e107424. PMID: 25232828, PMCID: PMC4169411, PII: PONE-D-14-22736, DOI: 10.1371/journal.pone.0107424, ISSN: 1932-6203.
    Available from:
  • Cardin DB, Berlin JD. Pancreas cancer on the rise: are we up to the challenge? [editorial]. J. Natl. Cancer Inst [print-electronic]. 2013 Nov 11/20/2013; 105(22): 1675-6. PMID: 24203986, PII: djt316, DOI: 10.1093/jnci/djt316, ISSN: 1460-2105.
    Available from:
  • Goff LW, Benson AB, LoRusso PM, Tan AR, Berlin JD, Denis LJ, Benner RJ, Yin D, Rothenberg ML. Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. Invest New Drugs [print-electronic]. 2012 Feb; 30(1): 290-8. PMID: 20857171, DOI: 10.1007/s10637-010-9528-x, ISSN: 1573-0646.
    Available from:
  • Goff LW, Berlin JD. Advanced biliary tract cancers. Am Soc Clin Oncol Educ Book. 2012; 281-2. PMID: 24451749, PII: 203, DOI: 10.14694/EdBook_AM.2012.32.281, ISSN: 1548-8748.
    Available from:
  • Chan E, Lafleur B, Rothenberg ML, Merchant N, Lockhart AC, Trivedi B, Chung CH, Coffey RJ, Berlin JD. Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer. Am. J. Clin. Oncol. 2011 Dec; 34(6): 581-6. PMID: 21217396, PMCID: PMC3133812, DOI: 10.1097/COC.0b013e3181fe46a1, ISSN: 1537-453X.
    Available from:
  • Puzanov I, Lee W, Chen AP, Calcutt MW, Hachey DL, Vermeulen WL, Spanswick VJ, Liao CY, Hartley JA, Berlin JD, Rothenberg ML. Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. Clin. Cancer Res [print-electronic]. 2011 Jun 6/1/2011; 17(11): 3794-802. PMID: 21346148, PMCID: PMC3107910, PII: 1078-0432.CCR-10-2056, DOI: 10.1158/1078-0432.CCR-10-2056, ISSN: 1078-0432.
    Available from:
  • Castellanos EH, Cardin DB, Berlin JD. Treatment of early-stage pancreatic cancer. Oncology (Williston Park, N.Y.). 2011 Feb; 25(2): 182-9. PMID: 21456390, PII: 167379, ISSN: 0890-9091.
    Available from:
  • Backlund DC, Berlin JD, Parikh AA. Update on adjuvant trials for pancreatic cancer. Surg. Oncol. Clin. N. Am. 2010 Apr; 19(2): 391-409. PMID: 20159521, PII: S1055-3207(09)00118-5, DOI: 10.1016/j.soc.2009.11.003, ISSN: 1558-5042.
    Available from:
  • Strickland SA, Berlin JD. Hiccups: underappreciated and underrecognized. J Support Oncol. 2009 Jul; 7(4): 128-9. PMID: 19731576, ISSN: 1544-6794.
    Available from:
  • Goff LW, Rothenberg ML, Lockhart AC, Roth BJ, VerMeulen WL, Chan E, Berlin JD. A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies. Am. J. Clin. Oncol. 2008 Oct; 31(5): 413-6. PMID: 18838875, PII: 00000421-200810000-00002, DOI: 10.1097/COC.0b013e318168ef2a, ISSN: 1537-453X.
    Available from:
  • Stover DG, Lockhart AC, Berlin JD, Chan E, Sandler AB, Sosman JA, Middlebrook V, Nicol S, Rothenberg ML. Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer. Invest New Drugs [print-electronic]. 2008 Aug; 26(4): 339-45. PMID: 18463792, DOI: 10.1007/s10637-008-9133-4, ISSN: 0167-6997.
    Available from:
  • Bauer TM, Berlin JD. A 17 year-old man with an exon 11 mutation of CD-117 causing a gastrointestinal stromal tumor. Cancer Invest. 2008 Mar; 26(2): 182-4. PMID: 18259950, PII: 788770048, DOI: 10.1080/07357900701637824, ISSN: 1532-4192.
    Available from:
  • Berlin JD, Venook A, Bergsland E, Rothenberg M, Lockhart AC, Rosen L. Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma. Clin Colorectal Cancer. 2008 Jan; 7(1): 44-7. PMID: 18279576, PII: S1533-0028(11)70396-6, DOI: 10.3816/CCC.2008.n.006, ISSN: 1533-0028.
    Available from:
  • Chan E, Berlin JD. Controversies in the adjuvant treatment of pancreas cancer: a lack of knowledge or simply a lack of will?. Gastrointest Cancer Res. 2007 Sep; 1(5): 204-6. PMID: 19262710, PMCID: PMC2632532, ISSN: 1934-7820.
    Available from:
  • Berlin JD. Adjuvant therapy for pancreatic cancer: to treat or not to treat?. Oncology (Williston Park, N.Y.). 2007 May; 21(6): 712-8; discussion 720, 725. PMID: 17564327, PII: 169590, ISSN: 0890-9091.
    Available from:
  • Lockhart AC, Cropp GF, Berlin JD, Donnelly E, Schumaker RD, Schaaf LJ, Hande KR, Fleischer AC, Hannah AL, Rothenberg ML. Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer. Am. J. Clin. Oncol. 2006 Apr; 29(2): 109-15. PMID: 16601426, PII: 00000421-200604000-00001, DOI: 10.1097/, ISSN: 1537-453X.
    Available from:
  • Rothenberg ML, LaFleur B, Levy DE, Washington MK, Morgan-Meadows SL, Ramanathan RK, Berlin JD, Benson AB, Coffey RJ. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J. Clin. Oncol. 2005 Dec 12/20/2005; 23(36): 9265-74. PMID: 16361624, PII: 23/36/9265, DOI: 10.1200/JCO.2005.03.0536, ISSN: 0732-183X.
    Available from:
  • Lockhart AC, Rothenberg ML, Berlin JD. Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology. 2005 May; 128(6): 1642-54. PMID: 15887156, PII: S0016508505004658, ISSN: 0016-5085.
    Available from:
  • Lockhart AC, Berlin JD. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin. Oncol. 2005 Feb; 32(1): 52-60. PMID: 15726506, PII: S0093775404004658, DOI: 10.1053/j.seminoncol.2004.09.036, ISSN: 0093-7754.
    Available from:
  • Tedesco KL, Lockhart AC, Berlin JD. The epidermal growth factor receptor as a target for gastrointestinal cancer therapy. Curr Treat Options Oncol. 2004 Oct; 5(5): 393-403. PMID: 15341677, ISSN: 1527-2729.
    Available from:
  • Berlin JD. Current and future strategies for treating metastatic pancreatic cancer. Clin Adv Hematol Oncol. 2004 Aug; 2(8): 510-2. PMID: 16163230, ISSN: 1543-0790.
    Available from:
  • Lockhart AC, Howard M, Hande KR, Roth BJ, Berlin JD, Vreeland F, Campbell A, Fontana E, Fiorentini F, Fowst C, Paty VA, Lankford O, Rothenberg ML. A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors. Clin. Cancer Res. 2004 Jan 1/15/2004; 10(2): 468-75. PMID: 14760067, ISSN: 1078-0432.
    Available from:
  • Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J. Clin. Oncol. 2003 Jun 6/1/2003; 21(11): 2059-69. PMID: 12775730, PII: JCO.2003.11.126, DOI: 10.1200/JCO.2003.11.126, ISSN: 0732-183X.
    Available from:
  • Berlin JD, Rothenberg ML. Chemotherapeutic Advances in Pancreatic Cancer. Curr Oncol Rep. 2003; ((In Press)).
  • Meadows SM, Mulkerin D, Berlin J, Kolesar J, Warren D, Thomas JP. Phase II Trial of Perillyl Alcohol in Patients with Metastatic Colorectal Cancer. International Journal GI Cancer. 2003; ((In Press)).
  • Rothenberg M, Oza AM, Bigelow RH, Berlin JD, Marshall J, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG. Superiority of Oxaliplatin + Bolus & Infusional 5-FU/Leucovorin Over Either Therapy Alone in Patients with Progressive Colorectal Cancer Following Irinotecan + Bolus 5-FU/Leucovorin: Interim Results of a Phase III Trial. J Clin Oncology. 2003; ((In Press)).
  • Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG and Benson III AB. Phase III Study of Gemcitabine in Combination with Fluorouracil Versus Gemcitabine Alone in Patients with Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Onc. 2002; ((20)): 3270-5.
  • Berlin JD, Tutsch KD, Arzoomanian RZ, Alberti D, Binger, Feierabend C, Dresen A, Marnocha R, Pluda J, and Wilding G. Phase I and Pharmacokinetic Study of a Micronized Formulation of Carboxyamidotriazole (CAI), a Calcium Signal Transduction Inhibitor: Toxicity, Bioavailability and the Effect of Food. Clin Cancer Res. 2002; ((8)): 86-94.
  • Berlin JD. Targeting Vascular Endothelial Growth Factor in Colon Cancer. Oncology. 2002; ((16)): 13-5.
  • Liu G, Berlin J, Tutsch KD, Van Ummersen L, Dresen A, Marnocha R, Arzoomanian R, Alberti D, Feierabend C, Binger K, and Wilding G. Phase I Clinical and Pharmacokinetic Study of Oral Penclomedine (NSC 338720) in Adults with Advanced Solid Malignancy. Clin Cancer Res. 2002; ((8)): 706-11.
  • Meadows S, Thomas JP, Mulkerin D, Berlin JD, Bailey H, Binger K, Volkman J, Alberti D, Feierabend C, Marrocha R, Arzoomanian RZ, Wilding G. Phase I study of Eniluracil, Oral 5-Fluorouracil and Gemcitabine in Patients with Advanced Malignancy. Inv New Drugs. 2002; ((20)): 377-87.
  • Berlin JD, Rothenberg ML. Chemotherapy for Resectable and Advanced Pancratic Cancer. Oncology. 2001; ((15)): 1241-48.
  • Berlin JD. New Directions in the Treatment of Advanced Colorectal Cancer. Oncology. 2001; ((15)): 27-30.
  • Blanke CD, Haller DG, Benson AB, Rothenberg ML, Berlin J, Mori M, Hsieh Y, Miller LL. A Phase II Study of Irinotecan with 5-fluorouracil and Leucovorinin Patients with Previously Untreated Gastric Adenocarcinoma. Ann Oncol. 2001; ((12)): 1575-80.
  • Berlin J, Adak S, Vaughn DJ, Flinker D, Blaszkowsky L, Harris JE, and Benson III AB. A Phase II Study of Gemcitabine and 5-Fluorouracil in Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study (E3296). Oncology. 2000; ((58)): 215-8.
  • Berlin JD. Second-Line Therapy in Colorectal Cancer. Oncology. 2000; ((14)): 21-6.
  • Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, Benson III AB. An ECOG Phase I Trial of Protracted Venous Infusion 5-fluorouracil Plus Weekly Gemcitabine With Concurrent Radiation Therapy in Patients with Locally Advanced Pancreas Cancer: A Regimen With Unexpected Early Toxicity. J Clin Onc. 2000; ((18)): 3384-9.
  • Berlin J, Alberti D, Arzoomanian R, Feierabend C, Simon K, Morgan K, and Wilding G. A Phase I Study of Gemcitabine, 5-fluorouracil and Leucovorin in Patients with Advanced, Recurrent, and/or Metastatic Solid Tumors. Invest New Drugs. 1999; ((16)): 325-30.
  • Berlin J, Merrick HW, Smith TJ, Lerner H. Phase II Evaluation of Treatment of Hepatic Metastases from Colorectal Cancer and Adjuvant Hepatic Arterial Infusion of Floxuridine: An Eastern Cooperative Oncology GroupStudy (PB083). Am J Clin Oncol (CCT). 1999; 3((22)): 291-3.
  • Berlin J. Gemcitabine. Clinical Perspectives in Gastroenterology. 1999; ((2)): 106-11.
  • Kolesar JK, Johnson C, Freeberg BL, Berlin JD, and Schiller JH. Warfarin-5FU Drug Interaction-A Consecutive Case Series. Pharmacotherapy. 1999; 12((19)): 1445-49.
  • Berlin J, Propert K, Trump D, Wilding G, Hudes G, Glick J, Burch P, Keller A, Loehrer P. Phase II Study of 5-Fluorouracil and Leucovorin Therapy in Patients with Hormone Refractory Prostate Cancer: An Eastern Cooperative Oncology Group Study (E1889). Amer J Clin Oncol-Cancer Clin Trials. 1998; ((21)): 171-6.
  • Berlin J, Stewart JA, Storer B, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, and Wilding G. Phase I Cliical and Pharmacokinetic Trial of Penclomedine Utilizing a Novel, Two-Stage Trial Design. J Clin Oncol. 1998; ((16)): 1142-9.
  • Berlin J, Theisen J, Marnocha R. Gemcitabine (Gemzar) (7) CanceRx7. On Drugs and Therapeutics. 1998; ((1)): 202-4.
  • Berlin J, Tutsch KD, Hutson P, Cleary J, Rago RP, Zoomanian RZ, Alberti D, Feierabend C, Wilding G. Phase I Clinical and Pharmacokinetic Study of Oral Carboxyamidotriazole (CAI), a Signal Transduction Inhibitor. J Clin Oncol. 1997; ((15)): 781-9.
  • Schiller JH, Storer B, Berlin J, Wittenkeller J, Larson M, Pharo L, Berry W. Amifostine, Cisplatin and Vinblastine in Metastatic Nonsmall Cell Lung Cancer: A Report of High Response Rates and Prolonged Survival. J Clin Oncol. 1996; 14: 1913-21.
  • Berlin J, King AC, Tutsch K, Findlay JW, Kohler P, Collier M, Clendennin NJ, Wilding G. A Phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma. Invest New Drugs. 1994; 12: 137-41.